Nevro Corp Stock Price, News & Analysis

On August 25, 2021, Supermoon Capital launched a $36 million venture fund focused on early-stage startups innovating in the sleep sector. This fund is the first of its kind, targeting the growing 'Night Market™,' which is valued at $488 billion. Co-founded by Pat Connolly and Michael Masterson, the fund aims to address significant sleep issues affecting 75% of Americans. Investments include six startups, such as Clair Labs and Endel, aimed at improving sleep health through science-backed innovations.

Nevro Corp. (NYSE: NVRO), a leading medical device company, will be represented by Chairman, CEO, and President D. Keith Grossman at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 11:45 AM Eastern Time. Investors can access a live webcast and an archived recording of the presentation on Nevro's website. The company specializes in innovative solutions for chronic pain treatment, including its proprietary Senza spinal cord stimulation systems.

Nevro Corp. (NYSE: NVRO), a medical device leader in chronic pain solutions, announced that CEO D. Keith Grossman will present at the Wells Fargo Virtual Healthcare Conference on September 10, 2021, at 8:00 am ET. A live webcast of the presentation will be available on Nevro's investor website. Nevro specializes in innovative spinal cord stimulation systems, including the Senza, Senza II, and Senza Omnia, delivering proprietary 10 kHz Therapy. Investors are encouraged to monitor the company's website for updates and important information.

Nevro Corp. (NVRO) reported Q2 2021 revenues of $102.3 million, an 81% increase from the previous year. Despite a net loss of $15.8 million, non-GAAP adjusted EBITDA improved to $3.0 million. The FDA approved its 10 kHz spinal cord stimulation therapy for painful diabetic neuropathy, enhancing its market position. However, Q3 revenue guidance is set at $90-$93 million, reflecting a decrease of 14%-17% year-over-year. The company is cautious due to ongoing COVID-19 impacts on patient procedures and future growth prospects.

Nevro Corp. (NYSE: NVRO) has received FDA approval for its Senza® System to treat Painful Diabetic Neuropathy (PDN) using 10 kHz spinal cord stimulation. This makes it the only FDA-approved spinal cord stimulation system specifically indicated for PDN. The company will launch this therapy in the U.S. under the HFX™ branding. Nevro anticipates a mid-single digit million revenue contribution from PDN in 2021, primarily in Q4, with higher revenue expected in future years. The company also announced preliminary Q2 2021 revenue of approximately $102.3 million.

Nevro Corp. (NYSE: NVRO) has announced it will report its Q2 2021 financial results on August 4, 2021, after market close. A conference call to discuss these results will take place at 1:30 pm PT / 4:30 pm ET on the same day. Interested investors can join by phone or via a live webcast on Nevro's website. The company focuses on innovative solutions for treating chronic pain, highlighted by its proprietary 10 kHz Therapy, which has shown efficacy in reducing opioid use in many patients.

Nevro Corp. (NYSE: NVRO) announced data from the SENZA Non-Surgical Refractory Back Pain (NSRBP) Randomized Controlled Trial (RCT) will be presented at the ASIPP annual meeting from June 24-26, 2021. The study compares Nevro's 10 kHz spinal cord stimulation (SCS) plus Conventional Medical Management to CMM alone in 159 patients. Previous 3-month results indicated superior pain relief for the 10 kHz SCS cohort. The 6-month results will be shared by Dr. Kapural on June 25, with plans to publish findings in a peer-reviewed journal and follow participants for 24 months. An investor briefing will also take place on June 25.

Nevro Corp. (NYSE: NVRO) announced data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial will be presented at the American Diabetes Association (ADA) 81st Scientific Sessions from June 25-29, 2021. The study compares Nevro's 10 kHz spinal cord stimulation (SCS) to conventional medical management in 216 patients. Initial results showed significant pain relief and improved quality of life. CEO D. Keith Grossman emphasized the potential for FDA approval and market expansion, aiming to address a $3.5 to $5 billion market for PDN treatment.

Nevro Corp. (NYSE: NVRO) announced it will host an analyst and investor briefing on June 25, 2021, during the American Diabetes Association's 81st Scientific Sessions. The event, led by Chairman and CEO D. Keith Grossman, will provide updates on the SENZA-PDN and SENZA-NSRBP clinical studies, along with a Q&A session. Participants can join via conference call or through a live audio webcast. For more details, visit Nevro's website. Nevro specializes in innovative solutions for chronic pain management, notably through its proprietary 10 kHz therapy.